Recent studies have shown that systemic inflammation caused by periodontal disease (PD) can determine important changes in the coronary arteries, favoring atherosclerosis progression and the development of acute coronary syndromes (ACS). The aim of the ATHERODENT study (Protocol Record Number CM0117-ATD) is to assess the interrelation between PD, inflammation, and the progression of coronary atherosclerosis in patients with ACS. Material and methods: This case-control observational study will enroll 100 patients (group 1 -ACS and associated PD, and group 2 -ACS and no PD), in whom the following data will be collected: (1) demographic and clinical data; (2) cardiovascular risk factors; (3) full characterization of PD markers; (4) systemic inflammatory biomarkers; (5) imaging biomarkers derived from transthoracic echocardiography, computed tomography, coronary angiography, optical coherence tomography, and intravascular ultrasound; and (6) assessment of the presence of specific oral bacteria in samples of coronary plaques collected by coronary atherectomy, which will be performed during percutaneous revascularization interventions, when indicated in selected cases, in the atherectomy sub-study. The follow-up will be performed at 1, 3, 6, 12, 15, 18 , and 24 months. The primary endpoint of the study will be represented by the rate of major adverse cardiovascular events (MACE) in PD vs. non-PD patients and in correlation with: (1) the level of systemic inflammation triggered by PD and/or by ACS at baseline; (2) the vulnerability degree of atheromatous plaques in the coronary tree (culprit and non-culprit lesions); and (3) the presence and burden of oral bacteria in atheromatous plaques. Secondary endpoints will be represented by: (1) the rate of progression of vulnerability degree of non-culprit coronary plaques; (2) the rate of progression of atheromatous burden and calcium scoring of the coronary tree; and (3) the rate of occurrence of left ventricular remodeling and post-infarction heart failure. The ATHERODENT study has been registered in clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT03395041).
STUDY RATIONALE
Coronary artery disease (CAD) and its major forms of manifestation -stable angina and acute coronary syndromes (ACS), are the most common causes of morbidity and mortality worldwide.
1 In 2015, the total number of cardiovascular deaths was 17.7 million, representing 31% of all deaths. From the total number of cardiovascular deaths, almost 50% (7.4 million) are caused by CAD.
2
The underlying substrate of CAD is represented by atherosclerosis, a generalized chronic and progressive inflammatory disease determined by lipid accumulation in the sub-intimal arterial layer, which leads to progressive narrowing or blockage of coronary vessels. 3, 4 This process implies a proliferation of the smooth vascular cells due to invasion and accumulation of the macrophages at this site.
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Several pro-inflammatory mediators and cytokines (Interleukin-1, Interleukin-6, lymphocytes, alfa-tumor necrosis factor, and growth factors) contribute to the initiation of atheromatous plaque formation, favoring its progression and raising the risk of plaque rupture as a result of an increased plaque vulnerability. 6,7 These mediators alter the structure of the endothelium, leading to overexpression of several adhesion molecules such as VCAM and ICAM, which enable leucocytes to bind to the endothelium.
4
Epidemiologic studies identified various risk factors for CAD such as genetic factors, hypercholesterolemia, diabetes mellitus, smoking, or glucose intolerance. However, they are not specific for cardiovascular disease, being also associated with relevant triggers for other diseases such as periodontal disease (PD).
8
PD is a chronic inflammatory disease of the tissues supporting the teeth, resulting from the activity of oral bacteria organized on the surface of the teeth. In PD, chronic inflammation extends from the periodontal pockets into the tooth-supporting tissue and leads to tooth loss. 4, 8 The prevalence of this disease is about 20-50% of global population in developed and developing countries.
9
The microorganisms related with this disease are usu- showing an increased risk for developing an ACS.
15

STUDY OBJECTIVES
The primary objective of ATHERODENT is to assess the interrelation between PD, inflammation, and atheroscle- The secondary objectives of ATHERODENT are:
1. to study the correlation between PD and coronary plaque vulnerability;
2. to assess the correlation between PD and the severity of coronary atherosclerosis;
3. to assess the presence and burden of oral bacteria in coronary atheromatous plaques collected during atherectomy and their relation with plaque vulnerability and evolution following an ACS (in the atherectomy sub-study).
The protocol summary of the ATHERODENT study is presented in Table 1 .
STUDY DESIGN
ATHERODENT is a case-controlled observational clini- The ATHERODENT study has been registered in clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT03395041). Secondary:
1. To study the correlation between PD and coronary plaque vulnerability;
2. To assess the correlation between PD and severity of coronary atherosclerosis.
Study design ATHERODENT is a case-controlled observational clinical study.
Study population
The study will include 100 patients with ACS (unstable angina or NSTEMI-type acute myocardial infarction), who undergo invasive coronary angiography ± interventional revascularization according to local protocols, divided in 2 groups:
-Group 1 -patients with ACS in whom dental examination performed in the first 7 days after the index event revealed the presence of PD;
-Group 2 -patients with ACS in whom dental examination performed in the first 7 days after the index event did not reveal the presence of PD.
Inclusion criteria:
-patients aged at least 18 years;
-patients who have signed the written informed consent;
-patients with ACS (unstable angina or non-ST segment elevation myocardial infarction) occurring with maximum 7 days prior to enrollment.
Exclusion criteria:
-patient's refusal to participate in the study;
-sensitivity to the contrast substance;
-women of reproductive age who do not use contraceptive methods;
-pregnant women;
-any malignancy within the last 5 years;
-any disease or comorbidity that can reduce life expectancy to less than 2 years;
-acute or chronic renal failure;
-non-compliant patients who, in the opinion of the investigators, will not present to follow-up. Baseline will be considered as the moment of the index event and related hospitalization. The index event will be considered the ACS, and patients will be randomized in the study at maximum 7 days post-ACS. The follow-up visits will be performed at 1, 3, 6, 12, 15, 18, and 24 months after randomization. Figure 1 represents a diagram of the overall study design.
Groups and interventions
The study lot will consist of 100 patients with ACS (unstable angina or NSTEMI-type acute myocardial infarction), who undergo invasive coronary angiography ± interventional revascularization according to local protocols, divided in 2 groups:
• group 1 -patients with ACS in whom dental examination performed in the first 7 days after the index event revealed the presence of PD;
• group 2 -patients with ACS in whom dental examination performed in the first 7 days after the index event did not reveal the presence of PD.
• patients aged at least 18 years;
• patients who have signed the written informed consent;
• patients with ACS (unstable angina or non-ST segment elevation myocardial infarction) occurring with maximum 7 days prior to enrollment.
Exclusion criteria:
• patient's refusal to participate in the study;
• sensitivity to the contrast substance;
• women of reproductive age who do not use contraceptive methods;
• pregnant women;
• any malignancy within the last 5 years;
• any disease or comorbidity that can reduce life expectancy to less than 2 years;
• acute or chronic renal failure;
• non-compliant patients who, in the opinion of the investigators, will not present to follow-up.
study procedures
The following procedures will be performed at baseline: Follow-up will be performed at 1, 3, 6, 12, 15, 18, and 24 months after randomization, including assessment of clinical data, echocardiography, and registration of major adverse cardiovascular events and other adverse events.
In addition, complex imaging assessment using CT angiography will be performed at 2 years to assess atherosclerosis progression.
The study procedures are summarized in Table 2 .
Statistical analysis will be performed in the Laboratory 
STUDY ENDPOINTS/OUTCOME MEASURES
The primary endpoint of the study will be represented by the rate of major adverse cardiovascular events (MACE) 
CONCLUSIONS
The aim of this study is not only to determine the correlation between PD and coronary atherosclerosis but also to analyze the role of PD in triggering an ACS, having as a working hypothesis that both entities have chronic inflammation as a common substrate. ATHERODENT will be the first study to assess the vulnerability degree of atheromatous plaques and of the entire coronary tree in patients with ischemic heart disease and concomitant PD, using a complex imaging platform that will integrate multiple imaging-derived biomarkers in a multimodality approach (CT, IVUS, OCT).
The ultimate goal of the ATHERODENT study is to establish the role of PD not only in triggering an acute coronary event but also in the evolution of coronary atherosclerosis and ventricular remodeling after an ACS.
The findings of the ATHERODENT study can be useful in clinical practice for the assessment of the severity of coronary artery disease and for a better stratification of the cardiovascular risk in patients with coronary atherosclerosis and concomitant PD.
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